The U.S. Food and Drug Administration has approved Idhifa (enasidenib), an isocitrate dehydrogenase-2 inhibitor for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.
Idhifa is a prescription medicine used to treat people with acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation whose disease has come back or has not improved after first treatment.
Enasidenib is an active ingredient in Idhifa while the inactive ingredients are: colloidal silicon dioxide, hydroxypropyl cellulose, hypromellose acetate succinate, iron oxide yellow, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, sodium lauryl sulfate, sodium starch glycolate, talc and titanium dioxide
The drug may cause serious side effects like:nausea, vomiting, diarrhea, jaundice and lack of appetite.
haleplushearty.blogspot.com
No comments:
Post a Comment